Pilot Projects Program
试点项目计划
基本信息
- 批准号:10281660
- 负责人:
- 金额:$ 59.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAge-associated memory impairmentAgingAwardBiometryCardiovascular DiseasesClinicalClinical ResearchCollaborationsCommunitiesCommunity HealthCommunity OutreachCommunity ServicesDataData ScienceDevelopmentDiseaseEntrepreneurshipEthnic OriginEvaluationExtramural ActivitiesFacultyFinancial SupportFosteringFundingFunding MechanismsFunding OpportunitiesGeographyGoalsGrantGreat PlainsHealthHealth PrioritiesInstitutionIntellectual PropertyLegal patentMalignant NeoplasmsManuscriptsMental HealthMentorsModelingNebraskaOralOutcomePilot ProjectsProductivityPublishingRaceRecommendationResearchResearch DesignResearch PersonnelResearch Project GrantsResourcesRural PopulationScienceSubstance abuse problemTechniquesTechnologyTrainingTranslational ResearchTranslationsViolenceWorkWritingbasebehavioral healthcare systemsclinical carecommunity engagementdesignepidemiology studyhealth disparityimprovedinjury preventioninnovationinter-institutionalmedical specialtiesnovelobesity preventionobesity treatmentprogramspublic-private partnershipsocial determinantssuccesstooltranslational research programtrial design
项目摘要
Pilot Projects Program Project Summary
The Pilot Projects Program (PPP) administers funding mechanisms to develop and support the most promising
and novel investigator-initiated clinical and translational research (CTR) projects. Our overarching goal is to
provide the financial support, mentoring, and other resources that investigators need to generate preliminary
data and successfully compete for extramural grant funding. The program is designed to further 4 key
objectives: 1) to foster the development of successful CTR investigators, 2) to support and develop
interdisciplinary CTR teams, 3) to develop innovative tools and technologies that will support remote conduct of
CTR or improve health outcomes, and 4) support CTR that evaluates the diverse causes of health-related
disparities in the region. The PPP supports these overall objectives through two specific aims: Specific Aim 1)
administer a CTR Pilot Projects Program that facilitates innovative and collaborative CTR programs and
Specific Aim 2) collaborate with the Cores and partner institutions to provide developmental CTR resources to
expand the pool of CTR investigators and teams. To successfully meet these specific aims, the PPP supports
interdisciplinary, team-based research that spans all GP IDeA- CTR partner institutions across the CTR
spectrum. Building on lessons learned and successes over the past four years, the portfolio of offered PPP
funding opportunities will be strategically expanded to include: 1) Team Development Pilots to provide initial
funding to foster new team formation, 2) Team Research Pilots to provide funding to existing CTR teams, and
3) Tech Transfer Pilots to support translation of intellectual property into clinical and community applications.
Resources from partner institutions will be leveraged to increase the number of available awards as well as
fund specialty awards focused on specific diseases (e.g., cancer or cardiovascular disease). The Pilot Projects
Program will collaborate with all Cores to advance CTR, including the Biostatistics, Epidemiology and
Research Design (BERD) Core and Community Engagement and Outreach (CEO) Core on their pilot grant
opportunities to strengthen the capacity for data science and trial design research as well as community-based
CTR projects, and with the Professional Development (PDC) Core to expand training and mentoring for pilot
grant recipients. In combination, these interdisciplinary, silo-spanning efforts will further strengthen the capacity
for and success of CTR across all our partner institutions, reinforce local support for CTR-focused faculty, and
encourage sustainable intramural and interinstitutional collaboration on CTR for improved health outcomes for
Nebraska and across the Great Plains.
试点项目计划项目摘要
试点项目计划(PPP)管理资金机制,以开发和支持最有前途的项目。
以及新型制药商发起的临床和转化研究(CTR)项目。我们的首要目标是
为调查人员提供所需的财政支持、指导和其他资源,
数据,并成功地竞争校外赠款资金。该计划旨在进一步4键
目标:1)培养成功的CTR研究者,2)支持和发展
跨学科合作伙伴关系团队,3)开发创新工具和技术,支持远程开展
CTR或改善健康结果,以及4)支持CTR,评估健康相关的各种原因
该地区的差距。公私伙伴关系通过两个具体目标支持这些总体目标:
管理CTR试点项目计划,促进创新和合作CTR计划,
具体目标2)与核心和伙伴机构合作,提供发展合作伙伴关系资源,
扩大CTR调查员和团队的人才库。为了成功实现这些具体目标,PPP支持
跨学科、基于团队的研究,涵盖CTR中的所有GP IDEA- CTR合作机构
江西篇章根据过去四年的经验教训和成功经验,
资助机会将战略性地扩大到包括:1)团队发展试点,以提供初始的
2)团队研究试点,为现有的CTR团队提供资金,以及
3)技术转移试点,支持将知识产权转化为临床和社区应用。
将利用伙伴机构的资源,增加现有奖学金的数量,
基金专门奖侧重于特定疾病(例如,癌症或心血管疾病)。试点
该计划将与所有核心合作,以推进CTR,包括生物统计学,流行病学和
研究设计(BERD)核心和社区参与和推广(CEO)核心的试点赠款
加强数据科学和试验设计研究以及基于社区的
CTR项目,并与专业发展(PDC)核心,以扩大培训和指导试点
补助金领取者。这些跨学科、跨越孤岛的努力结合在一起,将进一步加强联合国的能力,
在我们所有的合作伙伴机构的CTR和成功,加强对CTR为重点的教师当地的支持,
鼓励可持续的校内和机构间合作,以改善卫生成果,
内布拉斯加州和大平原。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sarah A Holstein其他文献
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
基于达雷妥尤单抗的四联疗法治疗符合移植资格的新诊断的具有高细胞遗传学风险的多发性骨髓瘤
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:12.8
- 作者:
Natalie S. Callander;R. Silbermann;Jonathan L. Kaufman;K. Godby;J. Laubach;T. Schmidt;Douglas W Sborov;E. Medvedova;B. Reeves;B. Dhakal;Cesar Rodriguez;S. Chhabra;A. Chari;S. Bal;Larry D. Anderson;B. Dholaria;N. Nathwani;P. Hari;Nina Shah;N. Bumma;Sarah A Holstein;Caitlin Costello;A. Jakubowiak;T. M. Wildes;R. Orlowski;K. Shain;Andrew J Cowan;H. Pei;A. Cortoos;Sharmila Patel;Thomas S. Lin;Smith Giri;Luciano J Costa;Saad Z Usmani;Paul G Richardson;P. Voorhees - 通讯作者:
P. Voorhees
Sarah A Holstein的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sarah A Holstein', 18)}}的其他基金
Geranylgeranyl diphosphate synthase inhibitor therapy for multiple myeloma
香叶基香叶基二磷酸合酶抑制剂治疗多发性骨髓瘤
- 批准号:
10364685 - 财政年份:2021
- 资助金额:
$ 59.63万 - 项目类别:
Geranylgeranyl diphosphate synthase inhibitor therapy for multiple myeloma
香叶基香叶基二磷酸合酶抑制剂治疗多发性骨髓瘤
- 批准号:
10600005 - 财政年份:2021
- 资助金额:
$ 59.63万 - 项目类别:
Geranylgeranyl diphosphate synthase inhibitor therapy for multiple myeloma
香叶基香叶基二磷酸合酶抑制剂治疗多发性骨髓瘤
- 批准号:
10180333 - 财政年份:2021
- 资助金额:
$ 59.63万 - 项目类别:
Rab Geranylgeranylation: a Novel Therapeutic Target in Multiple Myeloma
Rab 香叶基香叶基化:多发性骨髓瘤的新治疗靶点
- 批准号:
9331012 - 财政年份:2013
- 资助金额:
$ 59.63万 - 项目类别:
Rab Geranylgeranylation: a Novel Therapeutic Target in Multiple Myeloma
Rab 香叶基香叶基化:多发性骨髓瘤的新治疗靶点
- 批准号:
8988538 - 财政年份:2013
- 资助金额:
$ 59.63万 - 项目类别:
Rab Geranylgeranylation: a Novel Therapeutic Target in Multiple Myeloma
Rab 香叶基香叶基化:多发性骨髓瘤的新治疗靶点
- 批准号:
8416249 - 财政年份:2013
- 资助金额:
$ 59.63万 - 项目类别:
Rab Geranylgeranylation: a Novel Therapeutic Target in Multiple Myeloma
Rab 香叶基香叶基化:多发性骨髓瘤的新治疗靶点
- 批准号:
8600246 - 财政年份:2013
- 资助金额:
$ 59.63万 - 项目类别:
相似海外基金
THE GENETICS AND FUNCTIONAL NEUROANATOMY OF AGE-ASSOCIATED MEMORY IMPAIRMENT
年龄相关记忆障碍的遗传学和功能神经解剖学
- 批准号:
7606738 - 财政年份:2007
- 资助金额:
$ 59.63万 - 项目类别:
THE GENETICS AND FUNCTIONAL NEUROANATOMY OF AGE-ASSOCIATED MEMORY IMPAIRMENT
年龄相关记忆障碍的遗传学和功能神经解剖学
- 批准号:
7717960 - 财政年份:2007
- 资助金额:
$ 59.63万 - 项目类别:
THE GENETICS AND FUNCTIONAL NEUROANATOMY OF AGE-ASSOCIATED MEMORY IMPAIRMENT
年龄相关记忆障碍的遗传学和功能神经解剖学
- 批准号:
7205360 - 财政年份:2004
- 资助金额:
$ 59.63万 - 项目类别:
CITICOLINE AND AGE ASSOCIATED MEMORY IMPAIRMENT
胞二磷胆碱与年龄相关的记忆障碍
- 批准号:
6305687 - 财政年份:1999
- 资助金额:
$ 59.63万 - 项目类别:
CITICOLINE AND AGE ASSOCIATED MEMORY IMPAIRMENT
胞二磷胆碱与年龄相关的记忆障碍
- 批准号:
6115572 - 财政年份:1998
- 资助金额:
$ 59.63万 - 项目类别:
A study on the biological features of age-associated memory impairment (AAMI).
年龄相关记忆障碍(AAMI)生物学特征的研究。
- 批准号:
09671003 - 财政年份:1997
- 资助金额:
$ 59.63万 - 项目类别:
Grant-in-Aid for Scientific Research (C).
CITICOLINE AND AGE ASSOCIATED MEMORY IMPAIRMENT
胞二磷胆碱与年龄相关的记忆障碍
- 批准号:
6276806 - 财政年份:1997
- 资助金额:
$ 59.63万 - 项目类别:
AGE-ASSOCIATED MEMORY IMPAIRMENT: COMMUNITY-BASED STUDY
与年龄相关的记忆障碍:基于社区的研究
- 批准号:
3386469 - 财政年份:1990
- 资助金额:
$ 59.63万 - 项目类别:
AGE-ASSOCIATED MEMORY IMPAIRMENT: COMMUNITY-BASED STUDY
与年龄相关的记忆障碍:基于社区的研究
- 批准号:
3386468 - 财政年份:1990
- 资助金额:
$ 59.63万 - 项目类别:
AGE-ASSOCIATED MEMORY IMPAIRMENT: COMMUNITY-BASED STUDY
与年龄相关的记忆障碍:基于社区的研究
- 批准号:
2247160 - 财政年份:1990
- 资助金额:
$ 59.63万 - 项目类别: